BioNTech stock price target lowered to $116 at TD Cowen on trial delays
NegativeFinancial Markets

BioNTech's stock price target has been lowered to $116 by TD Cowen due to delays in clinical trials. This adjustment reflects concerns about the company's progress and could impact investor confidence. As BioNTech navigates these challenges, the market will be watching closely to see how it affects their future developments and overall performance.
— Curated by the World Pulse Now AI Editorial System











